Efpixileukin alfa

依普西白介素α

Report date: 2026/04/16 20:00:17

Base Information

Drug NameEfpixileukin alfa
Drug Alias NameIL2-Fc (Xencor)IL-2-Fc fusion protein (Xencor)XmAb-564XmAb564XmAb-27564
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionInterleukin-2 receptor alpha chain agonists
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsPsoriasisDermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A